We are live on
!
Find out more
NCM
Nantahala Capital Management Portfolio holdings
AUM
$2.72B
1-Year Est. Return
121.58%
This Fund
S&P 500
This Quarter
Est. Return
+17.36%
1 Year Est. Return
+121.58%
3 Year Est. Return
+308.64%
5 Year Est. Return
+308.9%
10 Year Est. Return
+2,888.73%
AUM
$1.98B
AUM Growth
+$266M
(+16%)
Cap. Flow
+$123M
Cap. Flow
% of AUM
6.23%
Top 10 Holdings %
Top 10 Hldgs %
54.68%
Holding
148
New
19
Increased
38
Reduced
28
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fulcrum Therapeutics
FULC
|
+$35.4M |
| 2 |
Titan Machinery
TITN
|
+$24.4M |
| 3 |
BlackSky Technology
BKSY
|
+$19.4M |
| 4 |
America's Car Mart
CRMT
|
+$13.5M |
| 5 |
PWSC
PowerSchool Holdings, Inc.
PWSC
|
+$13.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pathward Financial
CASH
|
+$17.8M |
| 2 |
IMAX
IMAX
|
+$10.2M |
| 3 |
Bioventus
BVS
|
+$8.54M |
| 4 |
Establishment Labs
ESTA
|
+$6.68M |
| 5 |
RDNW
RideNow Group
RDNW
|
+$5.58M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 41.22% |
| 2 | Consumer Discretionary | 6.49% |
| 3 | Communication Services | 3.21% |
| 4 | Financials | 3.01% |
| 5 | Industrials | 2.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Neurogene
NGNE
$729M
| $1.77M | 0.09% |
42,279
-30,000
| -42% | -$1.16M |
|
102
BiomX
PHGE
$1.78M
| $1.77M | 0.09% |
+91,084
| New | +$3.3M |
|
103
Talphera
TLPH
$73.2M
| $1.71M | 0.09% |
1,992,519
| – | – |
|
|
RNTX
104
Rein Therapeutics
RNTX
$67.9M
| $1.64M | 0.08% |
464,367
| – | – |
|
|
SGRP
105
DELISTED
SPAR Group
SGRP
| $1.62M | 0.08% |
662,028
| – | – |
|
106
Eledon Pharmaceuticals
ELDN
$284M
| $1.49M | 0.08% |
600,000
| – | – |
|
107
Instil Bio
TIL
$50.3M
| $1.36M | 0.07% |
20,276
-107,016
| -84% | -$2.52M |
|
108
Altisource Portfolio Solutions
ASPS
$63.3M
| $1.31M | 0.07% |
136,376
| – | – |
|
|
CMPS
109
Compass Pathways
CMPS
$1.78B
| $1.26M | 0.06% |
+200,000
| New | +$1.41M |
|
110
Unicycive Therapeutics
UNCY
$138M
| $1.15M | 0.06% |
282,036
| – | – |
|
|
SSKN
111
DELISTED
Strata Skin Sciences
SSKN
| $1.11M | 0.06% |
403,917
+100,000
| +33% | +$312K |
|
112
CALL
uniQure
QURE
$3.2B
| $991K | 0.05% |
201,000
-42,000
| -17% | -$273K |
|
|
ANEB
113
DELISTED
Anebulo Pharmaceuticals
ANEB
| $986K | 0.05% |
511,073
| – | – |
|
|
OKUR
114
OnKure Therapeutics
OKUR
$164M
| $931K | 0.05% |
54,780
| – | – |
|
|
GORV
115
DELISTED
Lazydays
GORV
| $827K | 0.04% |
18,371
+1,704
| +10% | +$116K |
|
116
Perfect Corp
PERF
$190M
| $805K | 0.04% |
419,133
| – | – |
|
117
NeuroOne Medical Technologies
NMTC
$13.6M
| $791K | 0.04% |
133,127
-25,367
| -16% | -$127K |
|
118
Kiora Pharmaceuticals
KPRX
$11.4M
| $773K | 0.04% |
211,110
| – | – |
|
119
BRC Group Holdings
RILY
$292M
| $715K | 0.04% |
136,174
+112,198
| +468% | +$1.24M |
|
120
Gossamer Bio
GOSS
$86.1M
| $664K | 0.03% |
672,856
| – | – |
|
|
IMTXW
121
DELISTED
Immatics N.V. Warrants
IMTXW
| $572K | 0.03% |
248,506
| – | – |
|
122
Aprea Therapeutics
APRE
$7.98M
| $566K | 0.03% |
205,760
| – | – |
|
123
iShares Russell 2000 ETF
IWM
$81.5B
| $515K | 0.03% |
2,331
+815
| +54% | +$174K |
|
124
Children's Place
PLCE
$58.3M
| $454K | 0.02% |
+29,314
| New | +$259K |
|
125
Edgewise Therapeutics
EWTX
$4.84B
| $357K | 0.02% |
13,371
| – | – |
|
Similar funds
TAM
XL
NB
PA
BCM
SCM
HCM
GC
Nantahala Capital Management's Q3 2024 Portfolio in Review
As of Q3 2024, Nantahala Capital Management held 148 positions worth $1.98B, up 16% from $1.71B the previous quarter. Its ten largest holdings account for 55% of the portfolio.
Nantahala Capital Management deployed $123M of net new capital in Q3 2024, opening 19 new positions and adding to 38 existing holdings. Its largest new stake was Fulcrum Therapeutics: 4,777,912 shares worth $17.1M.
By sector, the portfolio is most concentrated in Healthcare at 41% of assets, up from 40% a quarter earlier, followed by Consumer Discretionary and Communication Services.
On the sell side, the largest reduction was Pathward Financial, an estimated $17.8M trimmed.
- Nantahala Capital Management's largest Q3 2024 buy was Fulcrum Therapeutics: 4,777,912 shares worth $17.1M.
- Nantahala Capital Management added most to America's Car Mart in Q3 2024, an estimated $13.5M increase.
- Nantahala Capital Management's biggest Q3 2024 reduction was Pathward Financial, cutting an estimated $17.8M.
- Nantahala Capital Management fully exited Avadel Pharmaceuticals in Q3 2024, selling an estimated $4.92M.
- Nantahala Capital Management's ten largest holdings make up 55% of its $1.98B portfolio in Q3 2024.
- Nantahala Capital Management opened 19 new positions and closed 8 in Q3 2024.
- Nantahala Capital Management's portfolio value rose 16% quarter-over-quarter to $1.98B.
Based on Nantahala Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.